ABSTRACT
Introduction United Nations sustainable development goals aim for the elimination of viral hepatitis as a public health threat by 2030, leading to efforts to upscale the availability and accessibility of hepatitis B virus (HBV) vaccination, diagnosis and treatment globally. However, a variety of societal factors, including beliefs, traditions, and stigma, can be a major obstacle to all of these interventions. We therefore set out to investigate how HBV is understood and described in communities in Uganda, and whether there is evidence of potential stigma.
Method We carried out a qualitative formative study in two sites in South Western Uganda: a village in Kalungu district (site A) and an area on the outskirts of Masaka town (site B). We undertook a rapid assessment to investigate how adults describe HBV infection and their perceptions about the infection. We collected data by conducting a transect walk, observations, community group discussions, and in-depth interviews, sampling a total of 131 individuals. We used inductive content analysis to extract key themes associated with HBV.
Results There is no specific word for HBV infection in local languages, and knowledge about this infection is varied. While some individuals were completely unfamiliar with HBV infection, some had heard of HBV. Radio was a common source of information. There was awareness of HBV as a cause of liver disease, limited knowledge regarding the cause, mode of transmission and treatment. Stigma in HBV may be rare in this community due to limited understanding and experience of HBV.
Conclusion There is an ongoing need to improve awareness and understanding of HBV in this community. Careful dissemination of accurate information is required to promote acceptance of interventions for prevention, diagnosis and treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JMo is funded by Leverhulme Mandela Rhodes Doctoral Scholarship. PCM is funded by the Wellcome Trust (grant ref 110110). The SHEBA project was supported by a project grant from the Medical Research Council Global Challenges Research Fund, GCRF (Principal Investigator Philippa Matthews). The MRC/UVRI and LSHTM is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. The Uganda General Population Cohort (GPC) staff have received support from THRiVE (https://thrive.or.ug/).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
Our study data are available on-line in the form of supplementary data, comprising a table of metadata and statements collected from 131 participants (Table S1), and a summary of key themes raised by the study (Table S2).
ABBREVIATIONS
- AIDS
- Acquired Immunodeficiency Syndrome
- GPC
- general population cohort, Uganda
- HBV
- hepatitis B virus
- HIV
- human immunodeficiency virus
- sSA
- sub Saharan Africa
- UK MRC
- United Kingdom Medical Research Council
- WHO
- World Health Organisation
